Literature DB >> 7028874

Binding of C-reactive protein to human lymphocytes. I. Requirement for a binding specificity.

K James, B Hansen, H Gewurz.   

Abstract

Our laboratory previously reported that C-reactive protein (CRP) binds selectively to T lymphocytes and inhibits certain of their reactivities in vitro. However, these findings could not be repeated using more highly purified CRP preparations even under a variety of experimental conditions. Purified CRP alone did not bind to peripheral blood lymphocytes (PBL); however, in the presence of a ligand such as pneumococcal C-polysaccharide (CPS), CRP binding was readily detectable both by immunofluorescence and by a radioassay established for this purpose. The optimal concentration of CRP, ratio of CRP:CPS, and time and temperature for reactivity were determined using both assays. A markedly enhanced rate of binding was observed after pre-equilibration of CRP with calcium. A small percentage (mean 3.0%; range 0.5 to 8.0%) of PBL bound complexed CRP, and saturation was reached with 200 microgram CRP/ml. Reactivity of CRP with a multimeric form of phosphocholine (PC) (KLH-PC44) led to binding comparable to that observed with CPS, whereas monomeric PC inhibited the binding. Thus, in the presence of a multimeric binding specificity, CRP binds to a small fraction of peripheral blood lymphocytes, which are characterized in the accompanying paper.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028874

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Comparison of the enzymatic sensitivities of the platelet receptor for human C-reactive protein and its functional relationship to the platelet IgG Fc receptor.

Authors:  B A Fiedel; J N Siegel; H Gewurz; R M Simpson; J M Izzi
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

2.  Binding of human C-reactive protein to monocytes: analysis by flow cytometry.

Authors:  S P Ballou; R P Cleveland
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

3.  C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis.

Authors:  Lin Zhang; Shan-Hui Liu; Tyler T Wright; Zhi-Yuan Shen; Hai-Yun Li; Wei Zhu; Lawrence A Potempa; Shang-Rong Ji; Alexander J Szalai; Yi Wu
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

4.  Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum.

Authors:  F C De Beer; B Shine; M B Pepys
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

5.  Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human C-reactive protein or crude lymphokine.

Authors:  P S Thombre; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition.

Authors:  L L Baum; B Johnson; S Berman; D Graham; C Mold
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

7.  Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity.

Authors:  L A Potempa; J M Zeller; B A Fiedel; C M Kinoshita; H Gewurz
Journal:  Inflammation       Date:  1988-08       Impact factor: 4.092

8.  Binding sites for C-reactive protein on human monocytes are distinct from IgG Fc receptors.

Authors:  J M Zeller; B M Kubak; H Gewurz
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

9.  Species of alpha-hemolytic streptococci possessing a C-polysaccharide phosphorylcholine-containing antigen.

Authors:  S H Gillespie; P H McWhinney; S Patel; J G Raynes; K P McAdam; R A Whiley; J M Hardie
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

10.  The acute phase response in parasite infection. Nippostrongylus brasiliensis in the mouse.

Authors:  L R Lamontagne; J Gauldie; A D Befus; K P McAdam; M L Baltz; M B Pepys
Journal:  Immunology       Date:  1984-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.